[go: up one dir, main page]

WO2001010842A3 - Melanocortin-4 receptor binding compounds and methods of use thereof - Google Patents

Melanocortin-4 receptor binding compounds and methods of use thereof Download PDF

Info

Publication number
WO2001010842A3
WO2001010842A3 PCT/US2000/021327 US0021327W WO0110842A3 WO 2001010842 A3 WO2001010842 A3 WO 2001010842A3 US 0021327 W US0021327 W US 0021327W WO 0110842 A3 WO0110842 A3 WO 0110842A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
melanocortin
binding compounds
receptor binding
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/021327
Other languages
French (fr)
Other versions
WO2001010842A2 (en
Inventor
Martin P Maguire
Mingshi Dai
Tricia J Vos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Priority to AU66216/00A priority Critical patent/AU6621600A/en
Priority to EP00953837A priority patent/EP1204645A2/en
Priority to JP2001515309A priority patent/JP2003528810A/en
Priority to CA002381008A priority patent/CA2381008A1/en
Priority to BR0012984-4A priority patent/BR0012984A/en
Priority to MXPA02001160A priority patent/MXPA02001160A/en
Publication of WO2001010842A2 publication Critical patent/WO2001010842A2/en
Publication of WO2001010842A3 publication Critical patent/WO2001010842A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

MC4-R binding compounds of the formula (I): B-Z-E wherein B is an anchor moiety, Z is a central moiety, and E is an MC4-R interacting moiety are discussed. Methods of using the compounds to treat MC4-R associated disorders, such as disorders associated with weight loss, are also discussed.
PCT/US2000/021327 1999-08-04 2000-08-04 Melanocortin-4 receptor binding compounds and methods of use thereof Ceased WO2001010842A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU66216/00A AU6621600A (en) 1999-08-04 2000-08-04 Melanocortin-4 receptor binding compounds and methods of use thereof
EP00953837A EP1204645A2 (en) 1999-08-04 2000-08-04 Melanocortin-4 receptor binding compounds and methods of use thereof
JP2001515309A JP2003528810A (en) 1999-08-04 2000-08-04 Melanocortin-4 receptor binding compounds and methods of use
CA002381008A CA2381008A1 (en) 1999-08-04 2000-08-04 Melanocortin-4 receptor binding compounds and methods of use thereof
BR0012984-4A BR0012984A (en) 1999-08-04 2000-08-04 Method for treating a condition associated with mc4-r in a mammal, compound binding to mc4-r, and pharmaceutical composition
MXPA02001160A MXPA02001160A (en) 1999-08-04 2000-08-04 Melanocortin-4 receptor binding compounds and methods of use thereof.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14728899P 1999-08-04 1999-08-04
US22327700P 2000-08-03 2000-08-03
US60/223,277 2000-08-03
US60/147,288 2000-08-03

Publications (2)

Publication Number Publication Date
WO2001010842A2 WO2001010842A2 (en) 2001-02-15
WO2001010842A3 true WO2001010842A3 (en) 2001-08-16

Family

ID=26844785

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/021327 Ceased WO2001010842A2 (en) 1999-08-04 2000-08-04 Melanocortin-4 receptor binding compounds and methods of use thereof

Country Status (7)

Country Link
EP (1) EP1204645A2 (en)
JP (1) JP2003528810A (en)
AU (1) AU6621600A (en)
BR (1) BR0012984A (en)
CA (1) CA2381008A1 (en)
MX (1) MXPA02001160A (en)
WO (1) WO2001010842A2 (en)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064091A2 (en) 2001-02-13 2002-08-22 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
US6465467B1 (en) 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
JP2003505435A (en) 1999-06-04 2003-02-12 メルク エンド カムパニー インコーポレーテッド Substituted piperidines as melanocortin-4 receptor gonists
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6699873B1 (en) 1999-08-04 2004-03-02 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
US7375125B2 (en) * 1999-08-04 2008-05-20 Ore Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
AU2001248753B2 (en) 2000-04-14 2004-12-23 Kureha Corporation Nitrogenous compounds and antiviral drugs containing the same
DZ3415A1 (en) 2000-08-31 2002-03-07 Chiron Corp GUANIDINOBENZAMIDES AS MC4-R AGONISTS.
AU2001295837A1 (en) * 2000-10-30 2002-05-15 Warner-Lambert Company Llc Aminoalkylpyrrolidine serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their synthesis
EP1341773A2 (en) * 2000-12-07 2003-09-10 Cv Therapeutics, Inc. Substituted 1,3,5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis
WO2002062766A2 (en) * 2001-02-07 2002-08-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
US6716840B2 (en) * 2001-04-09 2004-04-06 Chiron Corporation Guanidino compounds
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7354923B2 (en) 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
UA81749C2 (en) 2001-10-04 2008-02-11 Х. Луннбек А/С Derivated of phenylpiperazine as serotonin reuptake inhibitorS
US7064139B2 (en) * 2001-10-29 2006-06-20 Uniroyal Chemical Company, Inc. Method for treating retroviral infections
WO2003045313A2 (en) * 2001-11-27 2003-06-05 Merck & Co. Inc. 2-aminoquinoline compounds
AU2002351747B2 (en) 2001-12-21 2008-06-05 H. Lundbeck A/S Aminoindane derivatives as serotonin and norepinephrine uptake inhibitors
US20030195187A1 (en) * 2002-02-04 2003-10-16 Chiron Corporation Guanidino compounds
AU2003216274A1 (en) * 2002-02-11 2003-09-04 Neurocrine Biosciences, Inc. Pyrrole derivatives as ligands of melanocortin receptors
IL163940A0 (en) 2002-03-13 2005-12-18 Euro Celtique Sa Aryl substituted pyrimidines and the use thereof
US7034033B2 (en) 2002-05-23 2006-04-25 Chiron Corporation Substituted quinazolinone compounds
CN100334092C (en) * 2002-06-11 2007-08-29 三共株式会社 Process for producing cyclic thioether and synthetic intermediate thereof
US7396930B2 (en) 2002-06-11 2008-07-08 Sankyo Company, Limited Process for producing cyclic thioether and synthetic intermediate thereof
JP2004067673A (en) * 2002-06-11 2004-03-04 Sankyo Co Ltd Method for producing cyclic thioether and synthetic intermediate of the same
GB2389581A (en) * 2002-06-12 2003-12-17 Viaxxel Biotech Gmbh Hydrogenated pyrimidines and their use as inhibitors of deoxyhypusine-synthase or hypusination of eIF-5A
BR0305628A (en) 2002-07-09 2004-09-08 Palatin Technologies Inc Pharmaceutical composition for treating sexual dysfunction in a mammal comprising peptide and its use
KR100863667B1 (en) * 2002-09-11 2008-10-15 가부시끼가이샤 구레하 Amine Compound and Use Thereof
EP1558253A4 (en) * 2002-10-30 2007-07-25 Merck & Co Inc PIPERIDINYL-ALPHA-AMINOAMIDE MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY
DE60329030D1 (en) 2002-12-04 2009-10-08 Ore Pharmaceuticals Inc Melanocortin receptor MODULATORS
FR2852957B1 (en) * 2003-03-31 2005-06-10 Sod Conseils Rech Applic NOVEL IMIDAZO-PYRIDINE DERIVATIVES AND THEIR USE AS A MEDICINAL PRODUCT
AU2004226838B8 (en) 2003-04-04 2009-06-11 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
DE10316081A1 (en) * 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie New compounds with antibacterial activity
EP1651229A1 (en) 2003-05-23 2006-05-03 Chiron Corporation Guanidino-substituted quinazolinone compounds as mc4-r agonists
CA2545601A1 (en) 2003-11-19 2005-06-09 Chiron Corporation Quinazolinone compounds with reduced bioaccumulation
FR2862971B1 (en) * 2003-11-28 2006-03-24 Sod Conseils Rech Applic NOVEL BENZIMIDAZOLE AND IMIDAZO-PYRIDINE DERIVATIVES AND THEIR USE AS A MEDICINAL PRODUCT
DK1701940T3 (en) 2003-12-23 2008-09-08 Lundbeck & Co As H 2- (1H-indolylsulfanyl) benzylamine derivatives as SSRIs
US7932281B2 (en) 2004-03-10 2011-04-26 Kureha Corporation Amine-based compound and use thereof
AR052308A1 (en) 2004-07-16 2007-03-14 Lundbeck & Co As H DERIVATIVES OF 2- (1H-INDOLILSULFANIL) -ARILAMINE AND A PHARMACEUTICAL COMPOSITION CONTAINING THE COMPOUND
US20070021433A1 (en) * 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
AR054393A1 (en) 2005-06-17 2007-06-20 Lundbeck & Co As H DERIVATIVES OF BENZO (B) FURANO AND BENZO (B) THIOPHEN, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF THE REINFORCEMENT OF AMINA BOSS NEUTRANTS.
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
TW200819426A (en) 2006-08-31 2008-05-01 Lundbeck & Co As H Novel indane compounds
EP2103614A1 (en) * 2008-03-18 2009-09-23 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyrimidine, imidazopyrazine and imidazopyridazine derivatives as melanocortin-4 receptor modulators
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010125402A1 (en) 2009-04-30 2010-11-04 Novartis Ag Imidazole derivatives and their use as modulators of cyclin dependent kinases
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
EA201690035A1 (en) 2011-02-25 2016-05-31 Мерк Шарп Энд Домэ Корп. NEW CYCLIC DERIVATIVES OF AZABENZIMIDAZOLE, USED AS ANTI-DIABETIC AGENTS
JP2015525782A (en) 2012-08-02 2015-09-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Antidiabetic tricyclic compounds
CN104955807A (en) 2013-02-04 2015-09-30 默克专利股份公司 Positive allosteric modulators of mGluR3
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2016056606A1 (en) * 2014-10-07 2016-04-14 国立大学法人京都大学 Benzoisothiazolopyrimidine derivative and salt thereof,and viral infection inhibitor and drug
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
EA201992215A1 (en) 2017-03-20 2020-02-06 Форма Терапьютикс, Инк. Pyrrolopyrrole Compositions as Pyruvate Kinase Activators (PKR)
CN108084109A (en) * 2017-12-21 2018-05-29 南京工业大学 Synthesis method of 2, 5-disubstituted-1, 3, 4-oxadiazole
EP3749697A4 (en) 2018-02-05 2021-11-03 Bio-Rad Laboratories, Inc. CHROMATOGRAPHIC RESIN WITH A LIGAND WITH ANION EXCHANGE-HYDROPHOBIC MIXED MODE
EP3853234B1 (en) 2018-09-18 2025-04-23 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
US10675274B2 (en) 2018-09-19 2020-06-09 Forma Therapeutics, Inc. Activating pyruvate kinase R
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
IL281811B2 (en) 2018-10-01 2025-03-01 Genzyme Corp Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use
WO2021055807A1 (en) 2019-09-19 2021-03-25 Forma Therapeutics, Inc. Activating pyruvate kinase r
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
TWI874791B (en) 2020-02-18 2025-03-01 美商基利科學股份有限公司 Antiviral compounds
CA3171648A1 (en) 2020-02-18 2021-08-26 Gilead Sciences, Inc. Antiviral compounds
TWI883391B (en) 2020-02-18 2025-05-11 美商基利科學股份有限公司 Antiviral compounds
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
CN117120444A (en) 2021-04-16 2023-11-24 吉利德科学公司 Method for preparing carbanucleoside using amide
US12116380B2 (en) 2021-08-18 2024-10-15 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1418053A (en) * 1972-04-22 1975-12-17 Basf Ag 2- -o-alkylthio-phenyl-1,3-diazacycloalkene hydrohalides and their production
WO1997047316A1 (en) * 1996-06-10 1997-12-18 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
WO1999064002A1 (en) * 1998-06-11 1999-12-16 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3594380A (en) * 1969-02-18 1971-07-20 American Home Prod Isoquinolin-1(2h)-ones
US4122263A (en) * 1973-04-11 1978-10-24 Basf Aktiengesellschaft Production of 2-(o-alkylthiophenyl)-1,3-diazocycloalkene hydrohalides
DE3046366A1 (en) * 1980-12-09 1982-07-08 Bayer Ag, 5090 Leverkusen TRICYCLIC CYTOSINE DERIVATIVES FOR USE IN MEDICINAL PRODUCTS AND METHOD FOR THE PRODUCTION THEREOF
GB8619971D0 (en) * 1986-08-15 1986-09-24 Fujisawa Pharmaceutical Co Imidazole compounds
JPS63253073A (en) * 1987-04-08 1988-10-20 Taisho Pharmaceut Co Ltd 2-phenylbenzimidazole derivative
ZA923283B (en) * 1991-05-29 1993-01-27 Akzo Nv Phenoxyphenyl derivatives
JPH09176871A (en) * 1995-12-25 1997-07-08 Tamura Kaken Kk Water soluble pre-flux, printed circuit board and surface treatment of metal of circuit board
EA200200392A1 (en) * 1997-04-15 2002-08-29 Ссир THE METHOD OF OBTAINING EXTRACT FROM PLANTS OF TRICHOCAULON OR HODIA GENERA;
WO1999032482A1 (en) * 1997-12-19 1999-07-01 Eli Lilly And Company Hypoglycemic imidazoline compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1418053A (en) * 1972-04-22 1975-12-17 Basf Ag 2- -o-alkylthio-phenyl-1,3-diazacycloalkene hydrohalides and their production
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
WO1997047316A1 (en) * 1996-06-10 1997-12-18 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight
WO1999064002A1 (en) * 1998-06-11 1999-12-16 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A. KASK ET AL., BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 245, no. 1, 1998, pages 90 - 3, XP002159225 *
C. HASKELL-LUEVANO ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 40, no. 11, 1997, pages 1738 - 48, XP002159224 *
M. A. BEDNAREK ET AL., BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 261, no. 1, 1999, pages 209 - 13, XP002159223 *
See also references of EP1204645A2 *

Also Published As

Publication number Publication date
MXPA02001160A (en) 2002-07-02
AU6621600A (en) 2001-03-05
WO2001010842A2 (en) 2001-02-15
BR0012984A (en) 2002-07-16
EP1204645A2 (en) 2002-05-15
CA2381008A1 (en) 2001-02-15
JP2003528810A (en) 2003-09-30

Similar Documents

Publication Publication Date Title
WO2001010842A3 (en) Melanocortin-4 receptor binding compounds and methods of use thereof
WO2002062766A3 (en) Melanocortin-4 receptor binding compounds and methods of use thereof
WO2000046203A3 (en) G-protein coupled heptahelical receptor binding compounds and methods of use thereof
WO2002002525A3 (en) N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
MY129613A (en) Cannabinoid receptor binding compounds
IL142768A0 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CA2206754A1 (en) Benzimidazole derivatives with antihistaminic activity
AU3126600A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2002012166A3 (en) Triamine derivative melanocortin receptor ligands and methods of using same
WO1999041237A8 (en) Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
AU3713600A (en) Nitrosated and nitrosylated prostaglandins, compositions and metods of use
AU2420897A (en) Meta-substituted phenylene sulphonamide derivatives
WO2001098268A3 (en) Piperidine amides as modulators of chemokine receptor activity
CA2281844A1 (en) Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
ZA200006312B (en) Antibodies to CD23, derivatives thereof, and their therapeutic uses.
WO2003024401A3 (en) Piperizinones as modulators of chemokine receptor activity
AU6337999A (en) Core-extended perylene bisimides
WO2000044763A3 (en) Compositions for treating inflammatory response
WO2001028987A8 (en) Benzylcycloalkyl amines as modulators of chemokine receptor activity
AU2002213421A1 (en) Condensed pyridoindole derivatives
CA2379364A1 (en) Synthesis of zsm-5 and zsm-11
HK1045834A1 (en) Bradykinin receptor antagonists
WO1999026932A8 (en) By amidino group substituted heterocyclic derivatives and their use as anticoagulants
WO2001098270A3 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2001098269A3 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/001160

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2381008

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 66216/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000953837

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000953837

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642